NCT06157255 - An ADME Study of [14C]AZD4604 and the Absolute Bioavailability of AZD4604 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 16, 2024

Primary Completion Date

May 20, 2024

Study Completion Date

May 20, 2024

Conditions

Asthma

Interventions

DRUG

AZD4604 Inhalation Powder, 1 mg

3 mg dose, inhaled, fasted

DRUG

[14C]AZD4604 Solution for Infusion 6 μg/mL (NMT 37.0 kBq/5 mL)

30 μg, intravenous, fasted

DRUG

[14C]AZD4604 Oral Solution, 4 mg (NMT 37.0 kBq)

4 mg, oral, fasted

Trial Locations (1)

Research Site, Ruddington